title: Low expression of cyclinH and cyclin-dependent kinase 7 can decrease the proliferation of human esophageal squamous cell carcinoma.
abstract: BACKGROUND
  Increased expression of cyclinH (CCNH) and cyclin-dependent kinase 7 (CDK7) has a relationship with poor prognosis in most human cancers.
  
  
  OBJECTIVE
  Investigate the expression of CCNH and CDK7 in human esophageal squamous cell carcinoma (ESCC) and the effect of chemotherapy on their expression.
  
  
  METHODS
  Western blotting and immunohistochemistry were used to measure the expression of CCNH and CDK7 proteins in ESCC and adjacent normal tissue in 98 patients. We use Cell Counting Kit-8 and cell flow to analyze the effects of cisplatin and interference of CCNH and CDK7 in cell cycle process.
  
  
  RESULTS
  Immunohistochemical analysis showed that CCNH and CDK7 expression were significantly associated with unfavorable clinicopathologic variables. CCNH and CDK7 protein levels were elevated in ESCC tissues in comparison with adjacent normal tissues. Survival analysis revealed that CCNH and CDK7 overexpression were significantly associated with overall survival (P < 0.001). Cisplatin or interference of CCNH or CDK7 led cells to grow slowly. Overexpression of CCNH and CDK7 in TE1 cells can lead to resistance to cisplatin.
  
  
  CONCLUSIONS
  We can conclude that CCNH and CDK7 may play an important role in the tumorigenesis and development of ESCC. CCNH and CDK7 expression affected the chemotherapy of tumor.
authors: Department of Immunology, Medical College, Nantong University, 19 Qi-Xiu Road, Nantong 226001, Jiangsu, People's Republic of China.
authors: Jianguo
authors: J
authors: Zhang
authors: Xiaojing
authors: X
authors: Yang
authors: Yuchan
authors: Y
authors: Wang
authors: Hui
authors: H
authors: Shi
authors: Chengqi
authors: C
authors: Guan
authors: Li
authors: L
authors: Yao
authors: Xianting
authors: X
authors: Huang
authors: Zongmei
authors: Z
authors: Ding
authors: Yuejiao
authors: Y
authors: Huang
authors: Huijie
authors: H
authors: Wang
authors: Chun
authors: C
authors: Cheng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use; D056748:Cyclin H / Q000378:metabolism*; D018844:Cyclin-Dependent Kinases / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D000095043:Cyclin-Dependent Kinase-Activating Kinase
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C534751:CCNH protein, human; D056748:Cyclin H; D018844:Cyclin-Dependent Kinases; D002945:Cisplatin; D000095043:Cyclin-Dependent Kinase-Activating Kinase; C000722416:CDK7 protein, human